Changzhou Qianhong Biopharma Co Ltd - Asset Resilience Ratio
Changzhou Qianhong Biopharma Co Ltd (002550) has an Asset Resilience Ratio of 20.24% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Changzhou Qianhong Biopharma Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Changzhou Qianhong Biopharma Co Ltd's Asset Resilience Ratio has changed over time. See 002550 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Changzhou Qianhong Biopharma Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Changzhou Qianhong Biopharma Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥610.44 Million | 20.24% |
| Total Liquid Assets | CN¥610.44 Million | 20.24% |
Asset Resilience Insights
- Good Liquidity Position: Changzhou Qianhong Biopharma Co Ltd maintains a healthy 20.24% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Changzhou Qianhong Biopharma Co Ltd Industry Peers by Asset Resilience Ratio
Compare Changzhou Qianhong Biopharma Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Changzhou Qianhong Biopharma Co Ltd (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Changzhou Qianhong Biopharma Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.67% | CN¥273.83 Million ≈ $40.07 Million |
CN¥2.83 Billion ≈ $414.18 Million |
+4.72pp |
| 2023-12-31 | 4.95% | CN¥136.93 Million ≈ $20.04 Million |
CN¥2.77 Billion ≈ $404.76 Million |
+2.55pp |
| 2022-12-31 | 2.40% | CN¥67.48 Million ≈ $9.87 Million |
CN¥2.81 Billion ≈ $410.60 Million |
-0.32pp |
| 2021-12-31 | 2.72% | CN¥68.23 Million ≈ $9.98 Million |
CN¥2.51 Billion ≈ $367.06 Million |
-6.84pp |
| 2020-12-31 | 9.56% | CN¥234.28 Million ≈ $34.28 Million |
CN¥2.45 Billion ≈ $358.77 Million |
-13.04pp |
| 2019-12-31 | 22.59% | CN¥662.98 Million ≈ $97.01 Million |
CN¥2.93 Billion ≈ $429.38 Million |
-19.09pp |
| 2018-12-31 | 41.69% | CN¥1.32 Billion ≈ $193.89 Million |
CN¥3.18 Billion ≈ $465.09 Million |
-10.30pp |
| 2017-12-31 | 51.99% | CN¥1.58 Billion ≈ $231.61 Million |
CN¥3.04 Billion ≈ $445.48 Million |
-- |
| 2016-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥3.03 Billion ≈ $443.95 Million |
-- |
| 2015-12-31 | 0.36% | CN¥10.25 Million ≈ $1.50 Million |
CN¥2.83 Billion ≈ $414.58 Million |
-0.08pp |
| 2014-12-31 | 0.44% | CN¥10.23 Million ≈ $1.50 Million |
CN¥2.31 Billion ≈ $338.13 Million |
+0.43pp |
| 2013-12-31 | 0.02% | CN¥362.70K ≈ $53.07K |
CN¥2.07 Billion ≈ $302.36 Million |
0.00pp |
| 2012-12-31 | 0.02% | CN¥338.65K ≈ $49.56K |
CN¥1.93 Billion ≈ $282.04 Million |
0.00pp |
| 2011-12-31 | 0.02% | CN¥369.85K ≈ $54.12K |
CN¥1.85 Billion ≈ $271.18 Million |
-0.06pp |
| 2010-12-31 | 0.08% | CN¥431.60K ≈ $63.16K |
CN¥548.53 Million ≈ $80.27 Million |
-0.01pp |
| 2009-12-31 | 0.09% | CN¥464.10K ≈ $67.91K |
CN¥533.87 Million ≈ $78.12 Million |
0.00pp |
| 2008-12-31 | 0.09% | CN¥353.60K ≈ $51.74K |
CN¥391.74 Million ≈ $57.32 Million |
-0.15pp |
| 2007-12-31 | 0.24% | CN¥683.80K ≈ $100.06K |
CN¥288.56 Million ≈ $42.23 Million |
-- |
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more